Skip to Main Content
Skip Nav Destination

ACIP recommends more flexibility on use of Tdap vaccine :

October 23, 2019

Clinicians soon may have more options for using tetanus, diphtheria and acellular pertussis (Tdap) vaccines.

The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) voted Wednesday to allow Tdap to be used in three situations that typically call for Td vaccine:

  • decennial Td booster;
  • tetanus prophylaxis for wound management for people who previously have been vaccinated with Tdap and are not pregnant; and
  • catch-up immunization for people 7 years and older regardless of pregnancy status.

In the catch-up scenario, one of the doses (preferably the first) should be Tdap. Either Tdap or Td can be used for additional doses.

“The work group’s interpretation was that allowing this change would give increased flexibility to providers and that while there may be some additional benefit for pertussis control, there was not enough evidence to recommend Tdap over Td in these settings,” said Fiona Havers, M.D., M.H.S., who leads the work group.

ACIP members noted Tdap is more expensive, but providers still have the option of using Td.

Pedro L. Moro, M.D., M.P.H., CDC immunization safety officer, acknowledged safety data on multiple Tdap doses are limited but reassuring.

“Published data on closely spaced Tdap doses shows no increase in adverse events when Tdap or Td was administered as a second or third dose,” he said.

Tdap is routinely recommended for adolescents ages 11-12 years. On Wednesday, ACIP clarified its guidance regarding younger children who receive Tdap inadvertently or for catch-up vaccination. Officials said those who receive the vaccine at 7-9 years should get it again at age 11 or 12. Those who are at least 10 years of age do not need to repeat the adolescent Tdap dose.

If the CDC director approves ACIP’s recommendations, they will be published as official recommendations in the Morbidity and Mortality Weekly Report. The AAP will review the guidance and make its own recommendations.

Close Modal

or Create an Account

Close Modal
Close Modal